Core Viewpoint - Junshi Biosciences (01877) is expected to achieve significant revenue growth and a reduction in net losses by 2025, driven by improved commercialization capabilities and cost control measures [1][2]. Group 1: Financial Projections - The company anticipates a revenue of approximately 2.5 billion yuan for the year 2025, representing a year-on-year growth of about 28.32% [1]. - Research and development expenses are projected to be around 1.353 billion yuan in 2025, reflecting a year-on-year increase of approximately 6.10% [1]. - The expected net loss attributable to shareholders for 2025 is around 873 million yuan, which is a reduction of about 31.85% compared to the previous year [1]. - After excluding the impact of share-based payments, the net loss is projected to be approximately 799 million yuan, indicating a decrease of about 37.62% year-on-year [1]. - The net loss attributable to shareholders, after excluding non-recurring gains and losses, is expected to be around 985 million yuan, a reduction of approximately 23.64% compared to the previous year [1]. Group 2: Product Performance - The company's revenue growth during the reporting period is primarily attributed to increased sales of commercialized drugs [2]. - The core product, Toripalimab injection (brand name: Tuoyi®), has seen a significant year-on-year increase in sales revenue in the domestic market [2]. - As of the announcement date, Tuoyi® has been included in the national medical insurance catalog for all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [2].

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, with Innovent leading the projects in China while Eli Lilly retains exclusive rights outside Greater China [1]. Group 1: Partnership Details - Innovent Biologics will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1]. - The collaboration marks the seventh partnership between Innovent and Eli Lilly, highlighting a long-standing relationship that has evolved from capital investment to product commercialization [2]. - Innovent has previously collaborated with Eli Lilly on multiple projects, including agreements that set records for cooperation amounts between multinational and local pharmaceutical companies [2][3]. Group 2: Financial Performance - In 2020, Innovent achieved total revenue of 3.844 billion yuan, a year-on-year increase of 266.9%, with product revenue reaching 2.368 billion yuan, a 133.0% increase [3]. - The company anticipates total product revenue of approximately 11.9 billion yuan in 2025, marking a 45% year-on-year growth and the first time surpassing 10 billion yuan in product revenue [7]. - Innovent aims to achieve a product revenue scale of 20 billion yuan by 2027 and plans to advance five core pipelines into global Phase III clinical trials by 2030 [7]. Group 3: Globalization Strategy - Innovent's collaboration model has become a crucial component of its product pipeline, with 18 approved products, many developed through partnerships [6]. - The company is focusing on reducing reliance on external collaborations while enhancing its core R&D capabilities [10]. - Innovent's internationalization journey reflects the broader trend of Chinese innovative pharmaceutical companies transitioning to global markets, emphasizing the need for quality and originality in innovation [10].

来源：科技日报 科技日报记者 李禾 斐缦生物董事总经理陈欣伟说："斐缦全新自研的可控自组装技术平台是胶原突破性的精准进化力，让 自组装过程被设计、可控制。"没有秩序的胶原蛋白是一堆散沙，容易被代谢、被降解，有秩序的胶原 蛋白才是支撑起皮肤弹性的"钢筋铁骨"。可控自组装技术的最大魅力就是实现了胶原蛋白的"定制化"， 完成从形成结构到形成特定需要结构的技术跨越。 复旦大学生物医学工程与技术创新学院青年研究员、上海皮肤健康概念验证中心执行主任马彦云博士围 绕活性胶原的结构特征、作用机制以及多场景应用价值，阐述了系统性研究结论与实践验证成果。据 悉，斐缦生物与复旦大学正在进行胶原蛋白的校企联合研究。双方将以胶原技术为支撑，围绕皮肤修 复、黏膜修复、再生医学乃至营养学等多个场景持续探索。 （受访者供图） 近日，"智构胶原·有序新生"2026斐缦生物"可控自组装技术"生态发布会在吉林长春举办。斐缦生物凭 借全新自研的可控自组装技术平台，首次实现胶原纤维的"定制化"，并建立了全链路品质管控体系。 ...

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance the global research and development of innovative drugs in oncology and immunology, marking a significant milestone in their long-term partnership [1] Group 1: Financial Aspects - Innovent Biologics received an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - Innovent Biologics retains the rights to all products in Greater China while Eli Lilly secures exclusive global development and commercialization rights outside this region [1] Group 2: Strategic Collaboration - This agreement represents the seventh collaboration between Innovent Biologics and Eli Lilly, further deepening their productive partnership [1] - The collaboration leverages Innovent's established antibody technology platform and efficient clinical capabilities to lead projects from drug discovery to clinical concept verification in China [1] - Eli Lilly will benefit from the global exclusive development and commercialization rights for the relevant projects outside Greater China [1]

根据合作协议，双方将发挥互补优势，加快推进创新药物的全球研发工作。信达生物依托自身成熟的抗 体技术平台及高效的临床能力，将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成） 的研发工作；礼来获得相关项目在大中华区以外的全球独家开发与商业化许可，信达生物保留相关项目 在大中华区的全部权利。 消息面上，信达生物公告，与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发进 程。根据协议条款，信达生物将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物还有 资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，信达生物有权就各产品在大中 华区以外的净销售额获得梯度的销售分成。本次协议为双方第七次合作，进一步深化了双方长期且富有 成效的合作伙伴关系。 智通财经APP获悉，信达生物(01801)高开逾4%，截至发稿，涨4.65%，报83.2港元，成交额1364.48万港 元。 ...

Group 1 - Shanghai is actively expanding high-level opening-up and placing greater emphasis on technological innovation as part of its "14th Five-Year Plan" [2] - The biopharmaceutical industry is one of the three key leading industries in Shanghai, with Boehringer Ingelheim being a global leader in biopharmaceuticals [2] - Shanghai aims to create a long-term, stable, transparent, and predictable development environment to provide new opportunities for global enterprises [2] Group 2 - Boehringer Ingelheim is committed to increasing its innovation investment in Shanghai and collaborating with partners to deepen innovation and research and development [3] - Carl Zeiss AG is focused on leveraging its brand, professional, and innovation advantages to enhance its regional headquarters' functions in Shanghai [3] - Both companies are encouraged to participate in building a more competitive industrial ecosystem and to achieve breakthrough innovations in global markets [3]

沃森生物在投资者互动平台表示，公司的生物制造业务在2025年完成首个产业化项目产能建设，在2026 年一季度实现投产，同时已经对接下游客户并建立合作关系。后续相关进展情况请持续关注公司的信息 披露。公司四价流脑结合疫苗目前处于III期临床研究阶段，公司将严格按照国家药品注册程序和要求的 有关规定开展相关工作。 ...

Core Viewpoint - The company announced that its self-developed VAV1 molecular glue degrader ICP-538 has been approved by the National Medical Products Administration (NMPA) for clinical research, marking it as the first in China and the second globally to enter clinical trials [1] Group 1: Product Development - ICP-538 is a novel oral, highly efficient, and selectively targeted VAV1-specific molecular glue degrader [1] - VAV1 is a key protein downstream of T cell and B cell receptors, which is crucial for developing treatments for various difficult-to-treat autoimmune diseases [1] Group 2: Target Indications - The drug is aimed at treating multiple challenging autoimmune diseases, including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) [1]

（记者 王瀚黎） 沃森生物（300142.SZ）2月9日在投资者互动平台表示，公司四价流脑结合疫苗目前处于III期临床研究 阶段，公司将严格按照国家药品注册程序和要求的有关规定开展相关工作。 每经AI快讯，有投资者在投资者互动平台提问：贵司四价流脑结合疫苗的 Ⅲ 期临床总结报告是否已完 成全部复核工作？是否存在影响申报的临床数据问题？ ...

（文章来源：第一财经） 据上海发布，上海市委书记陈吉宁近日分别会见了勃林格殷格翰股东委员会主席冯保和、蔡司集团总裁 兼首席执行官裴安德。 陈吉宁介绍了上海"十五五"规划相关情况。他说，生物医药是上海重点发展的三大先导产业之一，勃林 格殷格翰是全球领先的生物制药企业，欢迎持续加大在沪创新研发和业务布局力度，围绕基础研究、临 床试验、生产制造等加强新药开发合作，参与构建开放创新生态。用好东方枢纽国际商务合作区功能优 势，不断拓展新业务、新场景、新服务。蔡司是全球领先的光学和光电设备制造商，核心业务、战略愿 景与上海产业发展定位相契合，欢迎更好发挥企业品牌优势、专业优势、创新优势，进一步提升地区总 部功能作用，加大在沪研发制造布局，积极参与构建更具竞争力的产业生态，在面向全球市场、深化开 放合作中取得更多突破性创新性成果。上海将持续营造市场化、法治化、国际化一流营商环境，在常态 化听取企业意见建议中不断优化政策制度供给，提供便利高效服务，及时解决具体问题，支持各类企业 在沪取得更好发展。 ...